Biologics

Two medtech companies have partnered to develop 3D-printed regenerative joint implants.

The FDA's clinical hold on Ortho RIT's Ortho-R drug has been lifted, according to a Dec. 13 news release.

Sioux Falls, S.D.-based Sanford Health launched a clinical trial examining the effectiveness of treating osteoarthritis with stem cells across five joints, Sioux Falls Business reported Dec. 8.

The California Institute for Regenerative Medicine has awarded a $5.5 million grant to a University of California Irvine professor to study the use of stem cells to treat chronic cervical spinal cord injury.

Over the past five years, the U.S. has seen a significant spike in the number of clinics advertising stem cell treatments, which claim to treat a range of orthopedic, neurological and autoimmune conditions, among others.

Theradaptive's Osteo-Adapt SP spinal fusion implant received the FDA's breakthrough medical device designation, according to a Nov. 19 news release.

Pacira Biosciences completed its acquisition of Flexion Therapeutics, according to a Nov. 19 news release.

Orthobiologics company Bioventus has signed a lease agreement to double its current operations and manufacturing space in Cordova, Tenn.

A spine biologics company's $100 million investment deal and six more key updates in regenerative medicine in the last two months:

Houston-based FibroBiologics, a regenerative medicine company developing treatments for chronic disease using fibroblast cells, signed an agreement with a private investment group that will provide the company with up to $100 million over the next three years.